Skip to main content
Quanta Report
PoliticsLawyers for Purdue Pharma and various stakeholders aim to secure approval for a settlement plan addressing thousands of opioid-related lawsuits, amidst a backdrop of over 900,000 deaths in the U.S. since 1999 due to the opioid crisis.

Purdue Pharma Bankruptcy Settlement Nears Approval Amid Streamlined Opposition

As a bankruptcy judge prepares to review Purdue Pharma's settlement plan for opioid-related lawsuits, consensus among parties offers a quiet contrast to previous contentious debates.

Source: AP1 min read
Purdue Pharma Bankruptcy Settlement Nears Approval Amid Streamlined Opposition
Image via AP

In brief

In a notable shift from prior hearings, the impending approval of Purdue Pharma's bankruptcy settlement shows broad consensus among involved parties, despite some lingering dissent. The settlement seeks to allocate funds to opioid addiction recovery while demanding accountability from the Sackler family, as the opioid crisis continues to affect thousands across the U.S.

NEW YORK — A bankruptcy judge is expected to approve a comprehensive settlement plan for Purdue Pharma, the maker of OxyContin, aimed at resolving the multitude of lawsuits surrounding the company’s role in the ongoing opioid crisis. With a consensus emerging among various groups, including the Sackler family, government entities, and addiction recovery advocates, the case could mark a pivotal moment in addressing the aftermath of an epidemic that has claimed nearly 900,000 lives in the U.S. since 1999.

This week's hearings culminate in a significant shift in response, as out of over 54,000 personal injury claimants, only 218 opposed the settlement. Many are focusing on how best to utilize the settlement funds to combat opioid addiction. The decision has distanced itself from previous legal battles characterized by severe dissension, showcasing a largely united front in favor of action against the opioid epidemic.

Key components of the Settlement

The proposed settlement would require members of the Sackler family to contribute up to $7 billion and relinquish ownership of Purdue Pharma, with funds primarily directed towards addiction recovery and prevention initiatives. Approximately $850 million is earmarked to compensate individuals affected by Purdue’s opioid products, particularly those who have suffered from substance use disorders.

Several provisions also ensure that Sackler family members remain uninvolved in opioid production globally and that documents related to the opioid crisis are made public, increasing transparency. Critics have voiced concerns over the extent of individual compensation, questioning the adequacy of the funds for those directly impacted by addiction.

The Road Ahead

The outcome of the bankruptcy hearing not only impacts how funds would be allocated but also reflects broader societal challenges in addressing accountability in the opioid crisis. Anticipation surrounds the judge's ruling, while advocates hope that the settlement will bring meaningful change and assist in recovery efforts nationwide.

Topics

More on this story